How Tirzepatide Works for Weight Loss

Tirzepatide is a once-weekly injectable medicine that activates two gut-hormone receptors, GIP and GLP-1, to lower appetite and calorie intake.¹ The FDA approves it as Zepbound for weight reduction and moderate to severe obstructive sleep apnea in adults with obesity, and as Mounjaro for type 2 diabetes.^1,2 In the SURMOUNT-1 trial, adults without diabetes lost an average of 15.0% to 20.9% of their body weight over 72 weeks.³ A physician decides whether it fits your labs and history, and manages the plan from there.

What Tirzepatide Is

Tirzepatide is a single molecule that acts on two receptors, and you take it as one weekly injection. The Zepbound label describes it as "a GIP receptor and GLP-1 receptor agonist," which means it binds and switches on the receptors for two hormones your gut releases after a meal.¹ GLP-1 stands for glucagon-like peptide-1. GIP stands for glucose-dependent insulinotropic polypeptide.

The molecule also carries a fatty acid chain that binds albumin, a blood protein, and that extends its half-life enough for once-weekly dosing.¹

It is a prescription medicine, so your physician decides whether it fits your history before anything is dispensed.

How the Dual Mechanism Works in the Body

Tirzepatide works mainly through appetite. The Zepbound label states that it "decreases calorie intake."¹ The label adds that "the effects are likely mediated by affecting appetite," so you feel less hungry and eat less.¹ GLP-1 is a natural regulator of appetite, and nonclinical data indicate the added GIP activity may further reduce food intake.¹ Both receptor types sit in brain regions that regulate hunger.¹

Three other effects follow from the same receptors:

• Slower stomach emptying. Food leaves the stomach more slowly, which helps you feel full sooner. The label notes this delay is largest after the first dose and fades over time.¹
• Glucose-dependent insulin release. Tirzepatide raises insulin only when blood sugar is elevated and lowers glucagon, a hormone that raises blood sugar.¹ If your labs show insulin resistance, this effect is part of what your physician is treating.
• Fat-weighted weight loss. The label states that tirzepatide "lowers body weight with greater fat mass loss than lean mass loss."¹

FDA-Approved Tirzepatide Products

Two branded products contain tirzepatide, and the one you are prescribed depends on which FDA indication you meet.

Zepbound is approved, alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and maintain that reduction long term. It covers adults with obesity, or adults with overweight plus at least one weight-related condition. Zepbound is also approved to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity.¹

Mounjaro is approved to improve blood sugar control in adults and children 10 and older with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for them.²

The two labels share the same molecule and the same boxed warning.^1,2 The Zepbound label says you should not combine tirzepatide with another tirzepatide product or with any GLP-1 drug.¹ For brand-level differences, see Zepbound vs Mounjaro. For how Mounjaro compares with a semaglutide brand, see Mounjaro vs Ozempic.

Your prescriber picks the product that matches your diagnosis. A weight goal points to the Zepbound indication, and type 2 diabetes care points to Mounjaro.

Weight Loss Results From the SURMOUNT Trials

The SURMOUNT program is the series of phase 3 trials that tested tirzepatide for weight management.

If you do not have diabetes, SURMOUNT-1 is the trial closest to your situation. It enrolled 2,539 adults without diabetes who had a BMI of 30 or more, or 27 or more with a weight-related complication.³ Over 72 weeks, average weight change was -15.0%, -19.5% and -20.9% across the three dose levels tested, compared with -3.1% on placebo.³ Between 85% and 91% of people on tirzepatide lost at least 5% of their body weight, versus 35% on placebo.³ Eli Lilly, which makes tirzepatide, funded the trial.³

The three-year extension followed 1,032 SURMOUNT-1 participants who also had prediabetes for 176 weeks.⁴ Weight change ranged from -12.3% to -19.7% on tirzepatide versus -1.3% on placebo. Type 2 diabetes was diagnosed in 1.3% of the tirzepatide groups versus 13.3% of the placebo group.⁴ If your labs already show prediabetes, that result is worth raising with your physician.

SURMOUNT-4 tested what happens when people stop. Participants who completed a 36-week lead-in on tirzepatide lost an average of 20.9%. They were then randomized to continue or switch to placebo.⁵ Over the next 52 weeks, the continuing group lost a further 5.5%, while the placebo group regained 14.0%.⁵ The authors concluded that withdrawal "led to substantial regain of lost weight."⁵

SURMOUNT-4 supports treating tirzepatide as a long-term therapy, so your plan for what comes after the first year belongs in your first conversation with your physician.

Body Composition and Lean Mass

When you lose weight on tirzepatide, some of what you lose is lean mass. A substudy of 160 SURMOUNT-1 participants measured body composition with a DXA scan, a low-dose X-ray that separates fat from lean tissue.⁶ About 75% of the weight lost was fat mass and 25% was lean mass, in both the tirzepatide and placebo groups.⁶ The substudy was 73% female, so it gives a proportion and does not show a male-specific result.⁶

Lean mass includes muscle, water and organ tissue, so a DXA number is not a pure muscle number. Your plan may include an exercise program, and resistance training and protein intake are both in your control. The GLP-1 muscle loss page covers them in detail.

Sleep Apnea Results

The SURMOUNT-OSA authors describe excess body fat as a causal risk factor for obstructive sleep apnea, and Zepbound is FDA approved to treat moderate to severe OSA in adults with obesity.^1,7 The SURMOUNT-OSA program ran two 52-week trials, one in adults not using positive airway pressure (PAP) and one in adults already using it.⁷

The main measure was the apnea-hypopnea index (AHI), the figure your sleep study reports as the number of breathing pauses and shallow-breathing episodes per hour of sleep. Participants started near 50 events per hour. AHI fell by 25.3 events per hour on tirzepatide versus 5.3 on placebo in the first trial, and by 29.3 versus 5.5 in the second.⁷ Blood pressure, hsCRP (an inflammation marker) and sleep-related symptoms also improved.⁷

If you snore heavily or wake unrefreshed, a sleep study confirms OSA before tirzepatide enters the discussion for that indication.

Side Effects and Label Warnings

If you have side effects on tirzepatide, they are most likely to be digestive. The Zepbound label lists nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, hypersensitivity reactions, burping, hair loss and reflux as the most common.¹ In SURMOUNT-1, most of these were mild to moderate and occurred mainly while the dose was being increased.³ Side effects led to stopping treatment in 4.3% to 7.1% of people on tirzepatide, versus 2.6% on placebo.³

The label also carries warnings your physician screens you for before prescribing:

• Thyroid C-cell tumors (boxed warning). Tirzepatide caused these tumors in rats, and it is unknown whether it causes them in humans. It is contraindicated if you or a family member has had medullary thyroid carcinoma, or if you have MEN 2 syndrome.¹
• Pancreatitis. Acute pancreatitis has been observed with tirzepatide and GLP-1 drugs. If you develop persistent or severe abdominal pain, sometimes reaching the back, you need prompt medical review.¹
• Gallbladder disease. Acute gallbladder events were more common on treatment and were associated with weight reduction.¹
• Severe gastroparesis. Zepbound is not recommended for people with severe gastroparesis, a condition of very slow stomach emptying.¹
• Pregnancy and contraception. Tirzepatide may cause fetal harm. Women using oral contraceptives are advised to switch to a non-oral method, or add a barrier method, for 4 weeks after starting treatment and for 4 weeks after each dose increase.¹

Report every side effect to your physician, who can adjust the plan when symptoms persist.

Compounded Tirzepatide and FDA Status

Compounded tirzepatide is not an FDA-approved product. The FDA states that "compounded drugs are not FDA approved," which means the agency does not review them for safety, effectiveness or quality before they are sold.⁹ The FDA's position is that compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug.⁹

The FDA has also received adverse event reports possibly linked to compounded tirzepatide used at doses beyond the approved label. It has identified fraudulent compounded tirzepatide carrying false label information.⁹ The compounded semaglutide page explains how compounding works for this drug class.

Before you start, ask which product your prescription is for and whether it is FDA approved. You are entitled to a clear answer, and it shapes how your physician monitors you.

Who Tirzepatide Suits

Tirzepatide fits you if your weight or sleep apnea meets the label criteria and you have no contraindication.¹ You are a likelier candidate if you have obesity, or overweight with at least one weight-related condition. It also suits you if you are prepared to treat weight as a long-term condition.

It is a poor fit if you have a personal or family history of medullary thyroid carcinoma or MEN 2, severe gastroparesis, or a current or planned pregnancy.¹ Cost also shapes your decision, and the GLP-1 cost page breaks down what drives it.

If you are weighing tirzepatide against semaglutide, the semaglutide vs tirzepatide comparison lays out the head-to-head data. A telehealth weight loss program explains how supervised care is delivered remotely.

The Opt Take on Tirzepatide

Tirzepatide treats appetite, and appetite is one driver of weight among several. When we evaluate weight, a physician looks at insulin, leptin, ghrelin, cortisol, sex hormones and thyroid, along with metabolic rate, sleep, stress and eating habits. Your plan is built from that picture, so any prescription targets a cause your labs point to.

At Opt Health, the starting point is a panel of 55+ biomarkers, then a 1:1 review with an Opt Health physician who sets the plan. That plan may include a prescription shipped from our pharmacy, a diet plan developed by our team of nutritionists, and an exercise program. Labs and a physician consultation repeat every 3 to 4 months, so your physician can adjust the plan on what your numbers did.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.